BIONANO GENOMICS INC (BNGO) Fundamental Analysis & Valuation

NASDAQ:BNGO • US09075F4046

Current stock price

1.2 USD
+0.01 (+0.84%)
Last:

This BNGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BNGO Profitability Analysis

1.1 Basic Checks

  • In the past year BNGO has reported negative net income.
  • BNGO had a negative operating cash flow in the past year.
  • In the past 5 years BNGO always reported negative net income.
  • BNGO had a negative operating cash flow in each of the past 5 years.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • BNGO has a Return On Assets of -35.87%. This is amonst the worse of the industry: BNGO underperforms 80.36% of its industry peers.
  • BNGO has a Return On Equity of -59.42%. This is in the lower half of the industry: BNGO underperforms 71.43% of its industry peers.
Industry RankSector Rank
ROA -35.87%
ROE -59.42%
ROIC N/A
ROA(3y)-96.8%
ROA(5y)-70.55%
ROE(3y)-205.95%
ROE(5y)-138.5%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • BNGO has a Gross Margin of 46.25%. This is comparable to the rest of the industry: BNGO outperforms 46.43% of its industry peers.
  • In the last couple of years the Gross Margin of BNGO has grown nicely.
  • BNGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.28%
GM growth 5Y7.25%
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BNGO Health Analysis

2.1 Basic Checks

  • BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BNGO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BNGO has less shares outstanding
  • The debt/assets ratio for BNGO is higher compared to a year ago.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • BNGO has an Altman-Z score of -14.18. This is a bad value and indicates that BNGO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -14.18, BNGO is doing worse than 94.64% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that BNGO is not too dependend on debt financing.
  • The Debt to Equity ratio of BNGO (0.08) is better than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -14.18
ROIC/WACCN/A
WACC17.9%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • BNGO has a Current Ratio of 1.98. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
  • BNGO's Current ratio of 1.98 is on the low side compared to the rest of the industry. BNGO is outperformed by 62.50% of its industry peers.
  • BNGO has a Quick Ratio of 1.74. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.74, BNGO perfoms like the industry average, outperforming 44.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.74
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BNGO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 94.31% over the past year.
  • The Revenue has decreased by -7.37% in the past year.
  • The Revenue has been growing by 27.38% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)94.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.81%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y0.84%
Revenue growth 5Y27.38%
Sales Q2Q%-2.6%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.14% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 28.18% on average over the next years. This is a very strong growth
EPS Next Y23.52%
EPS Next 2Y31.86%
EPS Next 3Y23.65%
EPS Next 5Y17.14%
Revenue Next Year24.27%
Revenue Next 2Y35.63%
Revenue Next 3Y32.44%
Revenue Next 5Y28.18%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BNGO Valuation Analysis

4.1 Price/Earnings Ratio

  • BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BNGO's earnings are expected to grow with 23.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.86%
EPS Next 3Y23.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNGO Dividend Analysis

5.1 Amount

  • BNGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNGO Fundamentals: All Metrics, Ratios and Statistics

BIONANO GENOMICS INC

NASDAQ:BNGO (4/2/2026, 8:10:33 PM)

1.2

+0.01 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-23
Earnings (Next)05-12
Inst Owners10.61%
Inst Owner Change262.17%
Ins Owners3.19%
Ins Owner Change0%
Market Cap12.22M
Revenue(TTM)28.51M
Net Income(TTM)-26.39M
Analysts80
Price Target5.61 (367.5%)
Short Float %11.68%
Short Ratio2.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.14%
Min EPS beat(2)18.39%
Max EPS beat(2)97.9%
EPS beat(4)4
Avg EPS beat(4)49.54%
Min EPS beat(4)18.39%
Max EPS beat(4)97.9%
EPS beat(8)6
Avg EPS beat(8)2.94%
EPS beat(12)7
Avg EPS beat(12)4.31%
EPS beat(16)8
Avg EPS beat(16)-1.24%
Revenue beat(2)1
Avg Revenue beat(2)2.19%
Min Revenue beat(2)-0.74%
Max Revenue beat(2)5.12%
Revenue beat(4)2
Avg Revenue beat(4)0.64%
Min Revenue beat(4)-3.37%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)3.75%
Revenue beat(12)7
Avg Revenue beat(12)2.59%
Revenue beat(16)10
Avg Revenue beat(16)2.4%
PT rev (1m)-26.67%
PT rev (3m)-26.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.24%
EPS NY rev (1m)0%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-4.76
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS2.8
BVpS4.36
TBVpS3.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.87%
ROE -59.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.25%
FCFM N/A
ROA(3y)-96.8%
ROA(5y)-70.55%
ROE(3y)-205.95%
ROE(5y)-138.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.28%
GM growth 5Y7.25%
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.74
Altman-Z -14.18
F-Score4
WACC17.9%
ROIC/WACCN/A
Cap/Depr(3y)4.29%
Cap/Depr(5y)12.34%
Cap/Sales(3y)1.67%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.81%
EPS Next Y23.52%
EPS Next 2Y31.86%
EPS Next 3Y23.65%
EPS Next 5Y17.14%
Revenue 1Y (TTM)-7.37%
Revenue growth 3Y0.84%
Revenue growth 5Y27.38%
Sales Q2Q%-2.6%
Revenue Next Year24.27%
Revenue Next 2Y35.63%
Revenue Next 3Y32.44%
Revenue Next 5Y28.18%
EBIT growth 1Y56.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.28%
OCF growth 3YN/A
OCF growth 5YN/A

BIONANO GENOMICS INC / BNGO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIONANO GENOMICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to BNGO.


Can you provide the valuation status for BIONANO GENOMICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIONANO GENOMICS INC (BNGO). This can be considered as Overvalued.


What is the profitability of BNGO stock?

BIONANO GENOMICS INC (BNGO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BNGO stock?

The Earnings per Share (EPS) of BIONANO GENOMICS INC (BNGO) is expected to grow by 23.52% in the next year.